General Practice Doctors in Acoma, NM Accepting Medicare
1 General Practice doctors found. Showing 1 - 1
 Dr. Nadezda A Tretyakova, MD General Practice Medicare: Medicare Enrolled Practice Location: 80 B Veterans Blvd, I-40, Exit 102, Acoma, NM 87034 Phone: 505-552-5300 Fax: 505-552-5828 |
News Archive
UCLA professor receives ASA's Feinberg Award for clinical stroke research
Dr. Jeffrey L. Saver, professor of neurology at the David Geffen School of Medicine at UCLA and director of the UCLA Stroke Center, received the William Feinberg Award for Excellence in Clinical Stroke at the American Stroke Association's 2012 International Stroke Conference in New Orleans on Feb. 2.
LSUHSC to advance research on social, genetic, environmental and behavioral determinants of future obesity
Melinda Sothern, PhD, CEP, Professor and Director of the Behavioral and Community Health Sciences Program at LSU Health Sciences Center New Orleans School of Public Health, has been awarded $675,000 in grant funding to advance her research on the role of social, genetic, environmental and behavioral determinants of future obesity.
VeraLight's Scout DS Device receives Health Canada License approval
VeraLight Inc., a privately held medical device company, based here, today announced its Scout DS Device was granted a Health Canada Medical Device Licence for non-invasive diabetes screening.
SANYO releases whitepaper on its new cell culture CO2 incubator
SANYO North America's Biomedical and Environmental Division has released a new whitepaper showing that higher up-time ratios, based on new protocols that minimize incubator downtime when compared to conventional decontamination methods, can accelerate a return on investment in cell culture CO2 incubators that use hydrogen peroxide vapor (H2O2) in conjunction with narrow-bandwidth ultraviolet light and copper-enriched stainless steel.
Boehringer Ingelheim files MAA with EMA for afatinib approval
Today, Boehringer Ingelheim has announced the submission of a Marketing Authorisation Application to the European Medicines Agency (EMA) for approval of afatinib, the first irreversible ErbB Family Blocker, as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC). Afatinib has demonstrated unprecedented efficacy versus chemotherapy in the Phase III LUX-Lung 3 registration trial, which provides pivotal support for this submission.
› Verified 4 days ago